Cardio-Oncology: 2022 AHA/ACC/HFSA Heart Failure Guidelines

Cardio-Oncology

Cardio-Oncology: 2022 AHA/ACC/HFSA Heart Failure Guidelines

This infographic highlights the significance of identifying and monitoring cancer therapy-related cardiotoxicity (CTRC). It emphasizes a multidisciplinary, patient-centered approach to managing oncological therapies to mitigate the risks of cardiac dysfunction. Recommendations are provided for both pretherapy and ongoing cardiac monitoring, particularly for patients with cardiovascular risk factors or receiving potentially cardiotoxic treatments.

Produced by

Reviewed by

Dr. Amit Goyal

Dr. Eunice Dugan

Dr. Gurleen Kaur


CardioNerds Infographics

Explore our comprehensive collection of infographics, categorized by cardiovascular topics such as heart failure and transplantation, arrhythmias and electrophysiology, cardio-obstetrics, cardiovascular imaging, congenital heart disease, prevention, coronary artery disease, critical care, hypertension, pericardial disease, pulmonary hypertension, valvular heart disease, vascular disease, women’s cardiovascular health, diversity, inclusion, and more!

Feel free to download and share these visuals in presentations or on social media. Please use the infographics as provided—without altering or cropping out the creators’ credit.

For even more learning, explore the CardioNerds Tweetorial Page, featuring a curated collection of educational tweetorials!

You are currently viewing Cardio-Oncology: 2022 AHA/ACC/HFSA Heart Failure Guidelines